Last reviewed · How we verify
Placebo DLBS5055
Placebo DLBS5055 has no pharmacological mechanism of action, as it is an inert control substance.
DLBS5055 is a placebo developed by Duta Wacana Christian University. As a placebo, it does not contain any active pharmaceutical ingredients and is used primarily in clinical trials to serve as a control for comparison with active treatments. The lack of an FDA label indicates that it has not been evaluated or approved by the regulatory body for any specific medical use. Since it is a placebo, it does not have a defined mechanism of action, approved indications, or specific safety concerns beyond those typically associated with placebo administration. Commercially, it is not expected to generate revenue, and there are no competitors or patent issues to consider.
At a glance
| Generic name | Placebo DLBS5055 |
|---|---|
| Also known as | Placebo Herbapoten |
| Sponsor | Duta Wacana Christian University |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo, DLBS5055 contains no active pharmaceutical ingredient and produces no direct molecular or biological effect. It is used as a control comparator in clinical trials to assess the efficacy of active treatments through comparison against a non-therapeutic baseline. Any observed clinical benefit in placebo recipients would be attributable to placebo effect rather than drug action.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |